International Cancer Cluster Showcase 2020

geneos THERAPEUTICS

Exquisitely Personalized Immunotherapy for Cancer: GT-EPIC™

Dr. Niranjan Y. Sardesai
CEO & President, Co-Founder

June 8, 2020

Contact: Sardesai@geneostx.com

GENEOS CORPORATE THESIS

Cancer treatment innovation:

Personalized/Individualized

Immunotherapy (T cells as effectors)

Target differences in cancer versus normal cells

(e.g. Somatic variants in tumors; Cancer neoantigens)

With its GT-EPIC™ platform,

Geneos is developing cancer neoantigen - targeted, personalized immunotherapies

- Geneos established as a venture capital backed Immuno-Oncology startup
- GT-EPIC™ Platform: Optimized, DNA plasmid based, antigen-specific, T cell inducer
  - Demonstrated cancer antigen specific CD8+ T cells, and TILs
  - CPI combinations in the clinic in different IO settings

IMMUNE RESPONSES BY DESIGN

OPTIMIZED DNA NEOANTIGENS + pIL12 + CELLECTRA® ELECTROPORATION (EP)

- Personalized product has three components –
  - Optimized neoantigen DNA plasmid
  - IL-12 (pIL12)*: Cytokine immune-modulator
  - CELLECTRA® delivery device* (*in vivo* electroporation; EP)
- Favorable safety & immunogenicity profile*: 2,000+ subjects and 6,000+ immunizations



Current challenges of neoantigen vaccines	GT-EPIC™ Personalized Products
Lack of CD8 T Cell Responses (Mostly CD4s)	CD8 + CD4 responses
Neoantigen Payload Limitations (< 10-20)	>50 neoantigens/patient
Long Turnaround Time: 12 – 16 weeks	Turnaround time: 6-8 wks

Geneos' value proposition: (i) Clinical Efficacy; (ii) Cost Effective; (iii) Time Efficient

** CELLECTRA® EP Device, pIL12 and associated DNA safety and immunogenicity data licensed from Inovio Pharmaceuticals*

GENEOS NEOANTIGEN IMMUNOTHERAPIES DEMONSTRATE ABILITY TO COMBINE UPWARDS OF 60 NEOANTIGENS AND DRIVE SIGNIFICANT CONTROL OF TUMOR GROWTH

Mouse Tumor Challenge Study



Key takeaways:

- Formulations with > 60+ neoantigens
- No apparent interference seen
- Dilution of specific neoepitope dose with inclusion of additional irrelevant epitopes or control DNA does not impact tumor challenge efficacy



Ref: Duperret et al Canc Immunol. Res. (2019)

GENEOS CLINICAL PIPELINE



High degree of unmet clinical need; Large commercial impact

- HCC: 4th leading cause of cancer deaths; 800,000 new cases worldwide annually (6th largest); 18.4% 5 year survival (2nd worst)

GENEOS MILESTONES


cGMP Product for Patient #1

May 19, 2020
Manufactured first GMP Clinical Lot for the GT-30 study

February 7, 2020
GT-20 IND Open: Newly diagnosed GBM

December 31, 2019
GT-30 IND Open: Advanced HCC

July 22, 2019
Manufacturing supply agreement established with CDMO VGXI, Inc.

July 10, 2019
GT-10: First patient treated with GT-EPIC™ platform (Anaplastic Astrocytoma)

Feb 21, 2019
Geneos Therapeutics Secures $10.5 Million in Series A Financing to Develop the Next Generation of Neoantigen-Targeting Cancer Immunotherapies

Multiple alliance partners:

inovio · SANTÉ VENTURES · THE WISTAR INSTITUTE · VGXI QUALITY....IT'S IN OUR DNA® · Washington University in St. Louis School of Medicine

Upcoming milestones over next 12 months:
- Clinical execution of 3 Phase Ib/II clinical programs
- Clinical data from 18 patients

Geneos is seeking:
- Licensing partner(s) to support larger/later stage studies
- Investors/financing partners to participate in Series B